## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.7% below STRENGTH zone (4.0-10.0%); PEG 2.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($546.69)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Will Thermo Fisher's Asia Bioprocessing Tri-Hub Expansion Reshape Thermo Fisher Scientific's (TMO) Narrative?**
- Source: Simply Wall Street | 20251205T213123 | Somewhat-Bullish | Relevance: 100%
- Thermo Fisher Scientific is expanding its bioprocessing capabilities across Asia with a new Bioprocess Design Center in Hyderabad and enlarged facilities in Incheon and Singapore. This "tri-hub" network aims to support faster biologics and cell/gene therapy manufacturing, potentially deepening the company's role as an end-to-end partner in Asia's biopharmaceutical supply chain. The expansion aligns with Thermo Fisher's strategy to invest in capacity and capabilities, though it comes amidst challenges like stabilizing instruments demand and policy uncertainty in China.

**2. Knuff & Co LLC Sells 3,559 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251205T130900 | Bullish | Relevance: 100%
- Knuff & Co LLC reduced its stake in Thermo Fisher Scientific Inc. by 34.8% in Q2, selling 3,559 shares and now owning 6,669 shares valued at $2.70 million. Thermo Fisher Scientific (NYSE:TMO) reported strong quarterly earnings, beating analyst estimates with $5.79 EPS and $11.12 billion in revenue, and announced a $5.0 billion share buyback program and a quarterly dividend of $0.43 per share. Institutional investors hold 89.23% of the company's stock, while corporate insiders have recently sold shares totaling over $38 million.

**3. Thermo Fisher Scientific (TMO): Reassessing Valuation After Recent Share Price Gains**
- Source: Simply Wall Street | 20251204T154850 | Somewhat-Bullish | Relevance: 100%
- Thermo Fisher Scientific (TMO) has seen its share price rise by 3% in the last month and 18% over three months, prompting a reevaluation of its valuation. Despite trading below analyst targets, the company's strong innovation in analytical tools and AI integration positions it for future revenue and margin growth. While a narrative suggests it is 5.4% undervalued, risks such as persistent weakness in China or funding pressures could impact its performance.

**4. Thermo Fisher Scientific (TMO) SVP & General Counsel reports Form 4 stock sale**
- Source: Stock Titan | 20251203T215000 | Neutral | Relevance: 100%
- Thermo Fisher Scientific's SVP and General Counsel, Thomas B. Shropshire, Jr., reported the sale of 337.476 shares of company common stock on December 2, 2025, at a price of $580.37 per share. This transaction, filed as an SEC Form 4, resulted in him beneficially owning 5,079.524 shares directly afterward. The filing indicates a "Neutral" impact and "Negative" sentiment regarding the insider transaction.

**5. TMO Stock Benefits From New Bioprocess Design Center in Asia**
- Source: TradingView | 20251203T200635 | Bullish | Relevance: 100%
- Thermo Fisher Scientific (TMO) recently expanded its bioprocessing capabilities in Asia by opening a new Bioprocess Design Center in Hyderabad, India, and expanding existing centers in South Korea and Singapore. This strategic move aims to enhance speed, efficiency, and sustainability in biomanufacturing in the rapidly growing Asian biopharmaceutical market. The expansion is expected to boost market sentiment for TMO stock, which already shows strong earnings and revenue growth forecasts.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |
| 2025-12-01 | HSBC | $670 | $550 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-12-01 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.7% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.3M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Forward P/E 23.2x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +12%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $218.2B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 23.2 |
| Current P/E | 25.2 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.0% to -3.7% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.7pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-3.13), momentum weakening. RSI neutral at 50. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.68% (CS: 22) | Weak |
| RSI_14 | 49.7 | Neutral |
| MACD Histogram | -3.13 | Bearish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.191x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $572.77
- **Stop Loss:** $546.69 (4.6% risk)
- **Target:** $598.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 19
- **Position Value:** $10,882.63
- **Portfolio %:** 10.88%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*